Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mevrometostat plus enzalutamide versus placebo plus enzalutamide in untreated metastatic castration-resistant prostate cancer
NL-OMON59363Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Mevrometostat + enzalutamide with Placebo + enzalutamide (2 arms). Primary endpoint: Radiographic progression-free survival. Started Jun 2025; status: recruiting.
02
Drugs
mevrometostatenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON59363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59363.